The factors related to the enhanced efficacy of immunotherapy in EGFR‐driven lung cancer should be further investigated as it is certain that some patients with EGFR‐mutant lung cancer exhibit a remarkable and durable response to immunotherapy. The gene discussed is EGFR; the disease is lung cancer.